Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review

Satoshi Takanashi; Mitsuhiro Akiyama; Naoshi Nishina; Yuko Kaneko; Tsutomu Takeuchi

doi:10.1016/j.autrev.2021.102805

Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review

Satoshi Takanashi, Mitsuhiro Akiyama, Naoshi Nishina, Yuko Kaneko, Tsutomu Takeuchi

研究成果: Letter › 査読

本文言語	English
論文番号	102805
ジャーナル	Autoimmunity Reviews
巻	20
号	5
DOI	https://doi.org/10.1016/j.autrev.2021.102805
出版ステータス	Published - 2021 5月

ASJC Scopus subject areas

免疫アレルギー学
免疫学

文献へのアクセス

10.1016/j.autrev.2021.102805

他のファイルとリンク

引用スタイル

@article{28457d22351f46c79671cb80c2691a9b,

title = "Characteristics and prognosis of IgG4-related skin disease: A case report and systematic literature review",

author = "Satoshi Takanashi and Mitsuhiro Akiyama and Naoshi Nishina and Yuko Kaneko and Tsutomu Takeuchi",

note = "Funding Information: S.T., M.A., and N.N. report no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd., Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.",

year = "2021",

month = may,

doi = "10.1016/j.autrev.2021.102805",

language = "English",

volume = "20",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Characteristics and prognosis of IgG4-related skin disease

T2 - A case report and systematic literature review

AU - Takanashi, Satoshi

AU - Akiyama, Mitsuhiro

AU - Nishina, Naoshi

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

N1 - Funding Information: S.T., M.A., and N.N. report no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd., Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85104090340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104090340&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2021.102805

DO - 10.1016/j.autrev.2021.102805

M3 - Letter

C2 - 33727155

AN - SCOPUS:85104090340

SN - 1568-9972

VL - 20

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 5

M1 - 102805

ER -